KPV
C-terminal tripeptide (Lys-Pro-Val) of alpha-MSH. Keeps the parent hormone's anti-inflammatory and anti-microbial action without the pigmentation or libido effects. Orally bioavailable via the PepT1 transporter - a rarity among peptides.
Research chemicalNot WADA-listedOralAnti-inflammatoryAntifungal
Key facts
Common routesOral, SC, topical
Half-lifeShort (locally active longer)
Typical range200–500 mcg/day
Summary
KPV is the C-terminal tripeptide (Lysine-Proline-Valine) of alpha-melanocyte-stimulating hormone (α-MSH). It separates what's therapeutic about the parent molecule - anti-inflammatory and anti-microbial action - from what's hormonally active (pigmentation, libido, appetite). Three amino acids, a tightly defined mechanism.
The unusual property: KPV is taken up via the PepT1 transporter in the gut, allowing genuine oral bioavailability for a peptide. This makes it one of the few orally effective peptides in the catalog - and for the primary application (gut inflammation) the oral route is actually the mechanistically best route, not just the convenient one.
Mechanism notes
NF-κB inhibition
KPV suppresses NF-κB activation, the master switch for inflammatory cytokine production. Reduced TNF-α, IL-6, and IL-1β release. Same mechanism as the parent α-MSH; unlike MT-II or PT-141, it doesn't activate the melanocortin receptors meaningfully.
PepT1 transporter uptake
The intestinal di-/tripeptide transporter PepT1 recognises KPV and ferries it across the gut epithelium. Practical consequence: oral KPV reaches inflamed gut tissue directly - without first having to be SC-injected and systemically distributed. This is the rare case where oral is the more precise route, not just the more convenient one.
Anti-microbial activity
Directly disruptive to fungal cell membranes (notably Candida albicans biofilm formation) and some bacterial genera. This is also why KPV users with Candida overgrowth occasionally experience a Herxheimer-like reaction in the first few days - fatigue, mild flu-like symptoms - that's attributable to the anti-fungal action, not a KPV side effect.
Dosing patterns
Gut application (oral)
250–500 mcg orally twice daily, ideally 30 min before meals. Often dosed as a pH-protected capsule or as a BPC-157+KPV combination. The oral BPC-157 stack is the standard pairing for IBD/SIBO protocols - the two peptides address complementary aspects of gut repair.
Skin application (topical)
1–2% topical cream or spray on affected areas. Acts directly on keratinocytes via NF-κB inhibition. Useful for psoriasis, acne, eczema flares. Topical formulations are rare in grey-market supply; most users compound their own from reconstituted powder.
Systemic application (SC)
200–400 mcg SC daily for general inflammation reduction or in mast-cell-activation / Lyme / mold protocols. Subtler effects than the oral or topical routes - SC use is more about overall inflammatory containment than targeted tissue repair.
Evidence snapshot
Tier: Preclinical. Rating C - solid mechanistic and animal data, thin human RCT data for the isolated tripeptide. What human data exists is largely on α-MSH research that translates mechanistically but doesn't port 1:1.
Human data
No large RCTs for isolated KPV. Anecdotal user logs across Lyme/MCAS/CIRS and IBD communities are consistently positive for the oral application. Topical use in the acne / psoriasis community is increasingly documented.
Animal and in-vitro data
Dalmasso 2008: DSS-colitis model in mice - KPV significantly reduced inflammation and accelerated mucosal healing via the PepT1 pathway. Landy 2004: α-MSH and KPV inhibit NF-κB activation in keratinocytes. In-vitro studies show KPV inhibition of Candida albicans biofilm formation and hyphal growth.
Safety considerations
Very clean safety profile. Three amino acids means low antigenicity; the tripeptide doesn't bind the melanocortin receptors (MC1R for pigmentation, MC4R for libido/appetite) strongly enough to produce the parent α-MSH side effects. No cortisol effects, no sex hormone effects. The main practical risk is sourcing - oral formulations vary widely in quality and actual KPV delivered.
Common cautions
- Herxheimer-like reaction (fatigue, flu-like symptoms) in users with Candida overgrowth - typically self-limiting over 3–7 days
- Oral bioavailability depends on formulation - poorly compounded capsules can degrade before PepT1 uptake
- Grey-market formulations vary widely - a 250 mcg labelled capsule may actually deliver 50 mcg
- Not a magic bullet - for chronic gut disease, KPV supplements a full treatment regimen rather than replacing it